Spatiotemporally resolved metabolomics and isotope tracing reveal CNS drug targets.
10.1016/j.apsb.2022.11.011
- Author:
Bo JIN
1
;
Xuechao PANG
1
;
Qingce ZANG
1
;
Man GA
1
;
Jing XU
1
;
Zhigang LUO
1
;
Ruiping ZHANG
1
;
Jiangong SHI
1
;
Jiuming HE
1
;
Zeper ABLIZ
1
Author Information
1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- Keywords:
Ambient mass spectrometry imaging;
Central nervous system;
Drug candidate;
Drug targets;
Isotope tracing;
Spatiotemporally resolved metabolomics
- From:
Acta Pharmaceutica Sinica B
2023;13(4):1699-1710
- CountryChina
- Language:English
-
Abstract:
Deconvolution of potential drug targets of the central nervous system (CNS) is particularly challenging because of the complicated structure and function of the brain. Here, a spatiotemporally resolved metabolomics and isotope tracing strategy was proposed and demonstrated to be powerful for deconvoluting and localizing potential targets of CNS drugs by using ambient mass spectrometry imaging. This strategy can map various substances including exogenous drugs, isotopically labeled metabolites, and various types of endogenous metabolites in the brain tissue sections to illustrate their microregional distribution pattern in the brain and locate drug action-related metabolic nodes and pathways. The strategy revealed that the sedative-hypnotic drug candidate YZG-331 was prominently distributed in the pineal gland and entered the thalamus and hypothalamus in relatively small amounts, and can increase glutamate decarboxylase activity to elevate γ-aminobutyric acid (GABA) levels in the hypothalamus, agonize organic cation transporter 3 to release extracellular histamine into peripheral circulation. These findings emphasize the promising capability of spatiotemporally resolved metabolomics and isotope tracing to help elucidate the multiple targets and the mechanisms of action of CNS drugs.
